H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Pipeline Review, H2 2016', provides in depth analysis on H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) targeted pipeline therapeutics. 

The report provides comprehensive information on the H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) 
- The report reviews H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) targeted therapeutics and enlists all their major and minor projects 
- The report assesses H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) Overview 6
ATP synthase (EC 3.6.3.14) is an important enzyme that creates the energy storage molecule adenosine triphosphate (ATP). The majority of cellular energy in the form of adenosine triphosphate (ATP) is synthesized by the ubiquitous F1F0 ATP synthase. Power for ATP synthesis derives from an electrochemical proton (or Na+) gradient, which drives rotation of membranous F0 motor components. 6
Therapeutics Development 7
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Products under Development by Stage of Development 7
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Products under Development by Therapy Area 8
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Products under Development by Indication 9
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Products under Development by Companies 12
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Products under Development by Universities/Institutes 14
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 19
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Companies Involved in Therapeutics Development 20
Johnson & Johnson 20
Lycera Corp. 21
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Drug Profiles 22
bedaquiline fumarate - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
LYC-30937 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
LYC-51194 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
LYC-51661 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Small Molecule to Inhibit F0F1-ATP Synthase for Tuberculosis - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
TMC-207 Back Up - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Dormant Projects 32
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Featured News & Press Releases 33
Aug 22, 2016: Lycera Announces Initiation of Phase 2 Clinical Trial of LYC-30937-EC in Patients with Ulcerative Colitis 33
Jun 06, 2016: Speeding up drug discovery to fight tuberculosis 34
Mar 18, 2016: Lycera Announces Presentation of Positive Preclinical Results for Lead Candidate LYC-30937 at the 11th Congress of the European Crohn's and Colitis Organization (ECCO) 34
Aug 24, 2015: Janssen's SIRTURO to be commissioned by NHS England for the treatment of multi-drug resistant tuberculosis 35
Apr 30, 2015: Lycera Initiates Phase 1 Clinical Trial of LYC-30937, a First-In-Class ATPase Modulator for Inflammatory Bowel Disease 37
Nov 06, 2014: Janssen Collaborates for Continued Evaluation of Multidrug-Resistant Tuberculosis Treatment Regimens with SIRTURO (bedaquiline) 38
Oct 14, 2014: Bedaquiline Found Effective Against Tuberculosis In Indian Patients: Hinduja Hospital says 39
Mar 06, 2014: SIRTURO (bedaquiline) Receives Conditional Approval in the European Union for the Treatment of Multi-Drug Resistant Tuberculosis 39
Dec 20, 2013: SIRTURO Receives Positive Opinion from the Committee for MedicinalProducts for Human Use as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant Tuberculosis 40
Dec 19, 2013: Pharmstandard announces registration of Sirturo for MDR-TB 41
Jun 13, 2013: WHO Issues Interim Guidance On Bedaquiline To Treat Multidrug-Resistant Tuberculosis 42
Dec 31, 2012: FDA Grants Accelerated Approval For Sirturo As Part of Combination Therapy To Treat Adults With Pulmonary Multi-drug Resistant Tuberculosis 42
Dec 21, 2012: Public Citizen Urges FDA To Reject Accelerated Approval For Possibly Dangerous Anti-Tuberculosis Drug Bedaquiline 44
Nov 28, 2012: Janssen Announces FDA Advisory Committee Recommends Accelerated Approval Of Investigational Tuberculosis Treatment Bedaquiline 45
Nov 26, 2012: J&J's Tuberculosis Drug Bedaquiline Appears Safe And Well-tolerated, FDA Reviewers Say 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 17
Number of Products by Stage and Route of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 19
Pipeline by Johnson & Johnson, H2 2016 20
Pipeline by Lycera Corp., H2 2016 21
Dormant Projects, H2 2016 32